Related Experiment Video
Updated: May 28, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Drugs in development for chronic hepatitis C: a promising future.
1Division of Gastroenterology/Hepatology and Liver Disease Center, The Scripps Translational Science Institute and The Scripps Research Institute, Scripps Clinic, La Jolla, CA 92037, USA. pockros.paul@scrippshealth.org
Expert Opinion on Biological Therapy
|October 15, 2011
Summary
Direct-acting antiviral (DAA) drugs have revolutionized hepatitis C virus (HCV) treatment, improving sustained viral response rates. Ongoing research into combination therapies promises enhanced efficacy and tolerability for patients.
Area of Science:
- Hepatology and Viral Gastroenterology
- Pharmacology and Drug Development
- Infectious Diseases
Background:
- The introduction of direct-acting antiviral (DAA) drugs in 2011 significantly improved sustained viral response (SVR) rates for hepatitis C virus (HCV) genotype 1 infections.
- SVR rates reached up to 79% in clinical trials involving treatment-naïve or relapsed patients.
Purpose of the Study:
- To review the clinical application and advancements in direct-acting antiviral (DAA) drug therapy for hepatitis C virus (HCV).
- To discuss the efficacy, safety, and resistance patterns associated with first-generation protease inhibitors.
- To explore future directions and emerging combination therapies for HCV treatment.
Main Methods:
- Analysis of clinical trial data for first-generation protease inhibitors (telaprevir, boceprevir).
- Evaluation of genetic tests, HCV RNA assays, and resistance-associated variants.
- Review of DAA drug combinations, special population treatments, and management strategies for side effects and drug interactions.
Main Results:
- First-generation protease inhibitors demonstrated efficacy but required careful management of side effects and drug-drug interactions.
- Resistance-associated variants necessitate specific treatment strategies to minimize their development.
- Clinical trials highlighted the importance of understanding drug interactions and patient-specific factors.
Conclusions:
- Newer combination therapies, including protease inhibitors with polymerase and NS5A inhibitors, are being developed in both interferon-based and interferon-free regimens.
- The rapid advancement in drug development is expected to enhance both efficacy and tolerability for HCV patients.
- The use of DAAs represents a new era in HCV treatment, emphasizing the need for careful clinical application and ongoing research.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:16Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...